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intrOductiOn
Atrial fibrillation is the most common clini-
cally relevant arrhythmia (1), and its man-
agement is based on rate control (2), and 
antithrombotic therapy (3). Stroke and sys-
temic embolism are the most feared com-
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aBStract
introduction: Novel oral anticoagulants have been tested against warfarin for atrial fibrillation, yet no direct 
comparison is available. We thus aimed to perform pair-wise (direct) and warfarin-adjusted network (i.e. indi-
rect) meta-analyses of novel oral anticoagulants for atrial fibrillation. 
Methods: Databases were searched for randomized warfarin-controlled trials of novel anticoagulants for non-
valvular atrial fibrillation. The primary end-point was long-term stroke/systemic embolism. Odds ratios (95% 
intervals) were computed with RevMan and WinBUGS.
results: Seven trials (52701 patients) were included, focusing on apixaban, dabigatran, edoxaban and rivar-
oxaban. Pair-wise meta-analysis showed that after a weighted average of 23 months these novel anticoagulants 
lead to significant reductions in the risk of stroke/systemic embolism (odds ratio=0.81 [0.71-0.92], I2=23%) 
and all cause death (odds ratio=0.88 [0.82-0.95], I2=0%) in comparison to warfarin. Network meta-analysis 
showed that apixaban and dabigatran proved similarly superior to warfarin in preventing stroke/systemic em-
bolism (odds ratio=0.78 [0.62-0.96] for apixaban vs warfarin; odds ratio=0.66 [0.52-0.84] for high-dose dabi-
gatran vs warfarin; odds ratio for apixaban vs high-dose dabigatran=1.17 [0.85-1.63]), but apixaban was asso-
ciated with fewer major bleedings (odds ratio=0.73 [0.57-0.93]) and drug discontinuations (odds ratio=0.64 
[0.52-0.78]) than dabigatran. Rivaroxaban did not reduce stroke/systemic embolism (odds ratio=0.87 [0.71-
1.07]) or major bleedings in comparison to warfarin (odds ratio=0.87 [0.71-1.07]) and was associated with 
more major bleedings in comparison to apixaban (odds ratio=1.52 [1.19-1.92]). Data for edoxaban were in-
conclusive. 
conclusions: Novel oral anticoagulants appear as a very promising treatment option for atrial fibrillation.
Keywords: apixaban, atrial fibrillation, dabigatran, meta-analysis, rivaroxaban, systematic review, warfarin.
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plications of atrial fibrillation. Warfarin 
and other oral vitamin K antagonists have 
been proved effective and relatively safe in 
the prevention of thromboembolic risk of 
patients without bleeding diathesis but at 
moderate or high risk of stroke (4).
Warfarin has several limitations (1). First, 
it has a narrow therapeutic window and 
requires frequent monitoring of the inter-
national normalized ratio (INR). In addi-
tion, it has highly variable response (5), as 
well as multiple drug and food interactions 
(6). Finally, despite optimal warfarin treat-
ment, thromboembolic events still occur in 
several patients (7, 8).
Novel oral anticoagulants have been recent-
ly developed and formally tested in warfa-
rin-controlled phase III randomized trials 
(9-11), and others are currently completing 
pivotal trials (12-14). Specifically, apixaban 
(Eliquis; Bristol-Myers Squibb and Pfizer), 
edoxaban (Lixiana, Daiichi Sankyo and Eli 
Lilly) and rivaroxaban (Xarelto; Bayer and 
Johnson & Johnson) are oral direct Fac-
tor Xa (FXa) inhibitors, whereas dabiga-
tran etexilate (Pradaxa, Pradax or Prazaxa; 
Boehringer Ingelheim) is an oral prodrug 
which is converted by plasma and hepatic 
esterases to dabigatran, a direct Factor IIa 
(FIIa, i.e. thrombin) inhibitor (Table 1) 
(15). Promising data have been reported 
for all such novel drugs when compared to 
warfarin in patients with atrial fibrillation, 
yet it is unclear whether they do really rep-
resent a favorable breakthrough in the man-
agement of atrial fibrillation. In addition, 
the practicing physician remains uncertain 
about the relative strengths and weaknesses 
of each of these new treatment options as 
no direct comparison among them is avail-
able nor is foreseeable in the next future.
Network meta-analyses, as mixed treatment 
comparisons, are novel research designs 
capable of comparing different treatments 
exploiting common comparators, and their 
role in clinical research and practice has al-
ready been established (16). Whereas other 
network meta-analyses have already been 
reported focusing on dabigatran and anti-
platelet therapy (17, 18), no study is avail-
able comparing novel oral anticoagulants 
for atrial fibrillation. 
We thus aimed to perform pair-wise and 
warfarin-controlled network meta-analyses 
of novel oral anticoagulants for atrial fibril-
lation.
MetHOdS
Design and registration. The present review 
was performed according to the Cochrane 
Collaboration and PRISMA statements (19, 
20). In addition, it was prospectively regis-
tered on metcardio.org (protocol #3/2010). 
Search. MEDLINE/PubMed was searched 
according to this highly sensitive strategy, 
modified by Biondi-Zoccai et al (21), on 
September 10, 2011: (apixaban OR rivarox-
aban OR dabigatran OR (novel AND oral 
AND anticoagulant*)) AND atrial AND 
fibrillation AND (randomized controlled 
trial[pt] OR controlled clinical trial[pt] 
OR randomized controlled trials[mh] OR 
random allocation[mh] OR double-blind 
method[mh] OR single-blind method[mh] 
OR clinical trial[pt] OR clinical trials[mh] 
OR (clinical trial[tw] OR ((singl*[tw] OR 
doubl*[tw] OR trebl*[tw] OR tripl*[tw]) 
AND (mask*[tw] OR blind[tw])) OR 
(latin square[tw]) OR placebos[mh] OR 
placebo*[tw] OR random*[tw] OR re-
search design[mh:noexp] OR follow-up 
studies[mh] OR prospective studies[mh] 
OR cross-over studies[mh] OR control*[tw] 
OR prospectiv*[tw] OR volunteer*[tw]) 
NOT (animal[mh] NOT human[mh]) NOT 
(comment[pt] OR editorial[pt] OR meta-
analysis[pt] OR practice-guideline[pt] OR 
review[pt])). In addition, Google Scholar, 
The Cochrane Library, and Scopus were 
also searched for pertinent citations.
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References of retrieved studies were 
checked for additional studies (backward 
snowballing) and 2008-2011 conference 
proceedings of the American College of 
Cardiology, American Heart Association, 
and European Society of Cardiology scien-
tific sessions were also manually searched. 
No language restriction was enforced.
Selection. Study selection was performed 
by two independent reviewers (GBZ, ML), 
with divergences resolved by consensus. 
Citations were first scanned at the title/ab-
stract level. Shortlisted studies were then 
retrieved in full text. 
They were considered suitable for inclu-
sion if: reporting on randomized trials, 
table 1 - Pharmacokinetics of the novel oral anticoagulants.
apixaband dabigatrand,e edoxaban rivaroxaban
Target Factor Xa Factor IIa Factor Xa Factor Xa
Dosea 5 mg 75-150 mg 30-60 mg 20 mg
Frequency Twice daily Twice daily Daily Daily
Effect of Food None May delay (but not 
limit) absorption
None None
T1/2 12 h 12-17 h 6-10 h 5-9 h
TMAX 1-3 h 1 h 1-2 h 2-4 h
Metabolism Hepatic
(CYP3A4 - major)
Activation 
by esterases - renal
Renal – hepatic 
(CYP3A4 - minor)
Hepatic 
(CYP3A4 -major) -
renal
Renal
Impairment
Use 2.5 mg twice 
daily if SCr
≥1.5 mg/dL
Use 75 mg twice 
daily if CrCl=15-
30 mL/min*m2
Avoid use if CrCl 
<30 mL min*m2
Use 15 mg daily if CrCl 
= 30-49 mL/min*m2 - 
avoid use if CrCl 
<30 mL/min*m2
Hepatic
Impairment
Use with caution 
in mild to moderate 
(Child-Pugh B) - 
avoid use in severe 
(Child-Pugh C)
N/A Unknown Avoid use in moderate 
(Child-Pugh B) or 
severe (Child-Pugh C)
Drug
Interactions
CYP3A4 inhibitors 
or inducers - 
P-glycoprotein 
inhibitors 
or inducers
P-glycoprotein 
inhibitors 
or inducers
P-glycoprotein 
inhibitors 
or inducers
CYP3A4 inhibitors 
or inducers - 
P-glycoprotein 
inhibitors or inducers
Monitoringb Anti-Xa aPTT, ECT Anti-Xa Anti-Xa
Overdose
managementc
Unknown Unknown (can be 
dialyzed)
Unknown Unknown (likely not 
dialyzable – possibly 
protrombin complex 
concentratef
adose for atrial fibrillation; broutine monitoring not recommended due to linear dose response; cactivated prothrombin complex 
concentrate and recombinant factor VIIa have been proposed in overdose management; dapproved by the FDA for use in patients 
with non-valvular atrial fibrillation in the USA; ecapsules should be swallowed, do not chew, break, or open capsules; fa single 
study showed reversibility of rivaroxaban effect (and not of dabigatran effect) using protrombin complex concentrate (Eerenberg 
et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover 
study in healthy subjects. Circulation 2011; 124: 1573-79); CrCl=creatinine clearance; CY=cytochrome; ECT=ecarin clotting 
time; N/A=not applicable or available; SCr=serum creatinine; aPTT= activated partial thromboplastin time.
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comparing warfarin versus novel oral an-
ticoagulants, enrolling patients with atrial 
fibrillation (all the criteria had to be satis-
fied for inclusion). Studies were excluded if 
non-randomized, used other controls than 
warfarin, included patients without atrial 
fibrillation, or focused on ximelagatran/
melagatran, which is no longer developed 
given severe liver toxicity (22).
Abstraction and appraisal. Data abstraction 
and study appraisal were performed by two 
independent reviewers (GBZ, ML), with di-
vergences resolved by consensus. Key study 
and patient characteristics were extracted, 
including the following outcomes, reported 
at the longest available follow-up according 
to intention-to-treat principles:
1) stroke or systemic embolism (primary 
end-point);
2) all-cause death; 
3) major bleeding defined according to the 
Thrombolysis in Myocardial Infarction 
(TIMI) definition;
4) drug discontinuation.
 
In addition, study validity was appraised 
according to the risk of bias tool recom-
mended by The Cochrane Collaboration 
(23). All corresponding authors of short-
listed studies were directly contacted for 
data quality and completeness.
Analysis. Categorical variables are reported 
as events/patients at risk and were com-
pared with odds ratios (OR) with 95% 
confidence/credible intervals. Overall pair-
wise meta-analyses were performed with 
DerSimonian-Laird method and random-
effect model by means of RevMan 5.0.24 
(The Cochrane Collaboration, Copenhagen, 
Denmark), checking statistical consistency 
by means of I2 (24). 
In addition, small study effects were ap-
praised by visual inspection of funnel plots. 
Notably, no formal test for publication bias 
was used given the few included studies and 
variable comparators included. Subsequent-
ly, warfarin-adjusted network meta-anal-
yses (actually indirect treatment compari-
sons, given the star-shaped network) were 
performed using a fixed-effect model with 
WinBUGS 1.4.3, which behaves similarly 
to an indirect comparison method given 
the star shape. Each analysis was based on 
non-informative priors for effect sizes. Con-
vergence and lack of auto-correlation were 
checked and confirmed after a 100,000-sim-
ulation burn-in phase, and, finally, direct 
probability statements were based on an 
additional 500,000-simulation phase. De-
viance and deviance information criterion 
(DIC) were used to appraise model fit in 
comparison to a random-effect model. Com-
parisons are presented throughout using 
warfarin as reference treatment and order-
ing experimental treatments alphabetically.
reSultS
Studies. From a total of 7114 citations, 7 tri-
als were finally included (Tables 2-6). 
Specifically, two trials focused on apixaban 
(10, 25), two trials focused on dabigatran at 
variable dosages (9, 26), two trials focused 
on edoxaban at variable dosages (12, 13), 
and one trial focused on rivaroxaban (Ta-
bles 2-4) (11).
All included studies were randomized clini-
cal trials, varying from small phase II dose-
finding studies (12-13, 25-26), from large 
phase III pivotal studies with a non-inferi-
ority scope (9, 11). Inclusion and exclusion 
criteria were largely similar, but patients 
enrolled in the ROCKET AF trial of rivar-
oxaban versus warfarin had a higher preva-
lence of adverse clinical features, including 
a higher CHADS2 score (Tables 2-4).
Despite this, enrolment criteria were suf-
ficiently homogeneous (i.e. all studies in-
cluded patients in whom warfarin was con-
sidered beneficial) to ensure that the key 
assumption of any network meta-analysis 
44
G. Biondi-Zoccai, et al.
HSr Proceedings in intensive care and cardiovascular anesthesia 2013, Vol. 5
table 2 - Main features of included studies.
Study design Patients location drug Follow-up (months)
Primary
end-point
ARISTOTLE Non-inferiority 
RCT
18,201 Worldwide Apixaban 5 mg 
BID (2.5 mg in pa-
tients with two or 
more of the follow-
ing: age ≥80 years, 
body weight ≤60 
kg, or SCr ≥1.5 mg/
dL (133 μmol/L) 
vs warfarin (target 
INR 2.0-3.0)
22 Stroke or systemic 
embolism
ARISTOTLE-J Phase II
RCT
222 Japan Apixaban 2.5 mg 
BID vs apixaban 
5 mg BID vs war-
farin (target INR 
2.0-3.0)
3 Major bleeding 
and clinically
relevant 
non-major
bleeding
Chung 2011 Phase II 
RCT
253 Asia Edoxaban 30 mg 
QD vs edoxabn 60 
mg QD vs warfarin 
(target INR 2.0-
3.0)
3 Major, clinically 
relevant 
non-major 
and minor
bleeding
PETRO Phase II 
RCT
502 Worldwide Dabigatran 50 mg 
QD vs dabigatran 
50 mg BID vs dabi-
gatran 150 mg BID 
vs dabigatran 300 
mg BID vs warfa-
rin (target INR 2.0-
3.0)
3 Bleeding events
RE-LY Non-
inferiority
RCT
18,113 Worldwide Dabigatran 150 mg 
BID vs dabigatran 
110 mg BID vs war-
farin (target INR 
2.0-3.0)
24 Stroke or systemic 
embolism
ROCKET-AF Non-
inferiority 
RCT
14,264 Worldwide Rivaroxaban 20 
mg QD (15 mg if 
CrCl between 30-
49 ml per minute) 
vs warfarin (target 
INR 2.0-3.0)
24 Stroke 
(ischemic or 
hemorrhagic) 
and systemic 
embolism
Weitz 2010 Phase II 
RCT
1,146 Worldwide Edoxaban 30 mg 
QD vs edoxaban 30 
mg BID vs edoxa-
ban 60 mg QD vs 
edoxaban 60 mg 
BID vs warfarin 
(target INR 2.0-3.0)
3 Major and/or 
clinically relevant 
non-major 
bleeding
BID=bis in die; CrCl=creatinine clearance; INR=international normalized ratio; QD=quoque die; RCT=randomized clinical trial; 
SCr=serum creatinine.
novel anticoagulants for aF
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table 3 - Key selection criteria of included studies.
Study inclusion exclusion 
ARISTOTLE AF with 
CHADS2≥1
AF due to a reversible cause, moderate or severe mitral stenosis, conditions 
other than AF that required anticoagulation (e.g., a prosthetic heart valve), 
stroke within the previous 7 days, a need for aspirin at a dose of >165 mg 
a day or for both aspirin and clopidogrel, calculated creatinine clearance of 
<25 ml per minute.
ARISTOTLE-J AF with 
CHADS≥1
Recent stroke or TIA, valvular heart disease; sick sinus syndrome or severe 
conduction disturbance; non-cardiogenic stroke requiring aspirin >100 mg/
day or concomitant aspirin and antiplatelet agents; contraindications for 
warfarin use; severe or refractory hypertension; New York Heart Associa-
tion class IV heart failure; current thrombocytopenia: alanine aminotrans-
ferase or aspartate aminotransferase ≥2 × upper limit of normal; creatinine 
clearance <25 ml/min by Cockcroft Gault calculation; known or suspected 
hereditary bleeding tendencies; and scheduled electrical, pharmacological, 
or surgical cardioversion during the treatment period.
Chung 2011 AF with 
CHADS2≥1
Previous valve surgery, contraindication to anticoagulants, known bleeding 
disorder, conditions associated with high risk of bleeding (e.g. past history of 
major bleeding; uncontrolled hypertension; uncontrolled diabetes; haemor-
rhagic disorder; significant thrombocytopenia), ongoing treatment with an 
antiplatelet agent, AF secondary to other reversible disorders, acute coro-
nary syndrome or revascularization procedures, stroke, transient ischaemic 
attack, any major surgery within the previous 30 days, left ventricular an-
eurysm or atrial myxoma, impaired hepatic function, serum creatinine ≥1.5 
mg/dl, women of child-bearing potential without adequate contraception, 
pregnancy or lactation.
PETRO AF with 
CHADS2≥1
Mitral stenosis, prosthetic heart valves, planned cardioversion, recent (<1 
month) myocardial infarction, recent stroke or TIA, coronary stent place-
ment within 6 months, any contraindication to or another indication for 
anticoagulant therapy, major hemorrhage in the past 6 months, glomerular 
filtration rate <30 ml/min, abnormal liver function, risk of pregnancy, in-
vestigational drug use within 30 days, or any other condition that would not 
allow participation in the study.
RE-LY AF with 
CHADS2≥1
Severe heart-valve disorder, stroke within 14 days or severe stroke within 6 
months before screening, a creatinine clearance <30 ml per minute, active 
liver disease, and pregnancy.
ROCKET-AF AF with 
CHADS2≥2
Mitral valve stenosis, prosthetic heart valve; planned cardioversion (electri-
cal or pharmacological); AF due to a reversible cause; active endocarditis; ac-
tive internal bleeding; platelet count <90,000/μL at the screening visit; sus-
tained uncontrolled hypertension; severe, disabling stroke within 3 months 
or any stroke within 14 days before the randomization visit; TIA within 
3 days before the randomization visit; indication for anticoagulant therapy 
for a condition other than atrial fibrillation; aspirin >100 mg daily; aspirin 
in combination with thienopyridines within 5 days before randomization; 
intravenous antiplatelets within 5 days before randomization; fibrinolytics 
within 10 days before randomization; systemic treatment with a strong in-
hibitor or inducer of cytochrome P450 3A4, such as ketoconazole or prote-
ase; hemoglobin <10 g/dL at the screening visit; pregnancy or breast-feed-
ing: any other contraindication to warfarin; known HIV infection at time 
of screening; renal clearance <30 mL/min at the screening visit; known 
significant liver disease.
46
G. Biondi-Zoccai, et al.
HSr Proceedings in intensive care and cardiovascular anesthesia 2013, Vol. 5
Weitz 2010 AF with 
CHADS2≥2
Mitral valve disease, endocarditis, or a mechanical valve; contraindications 
to anticoagulation therapy, including a known bleeding disorder, recent ma-
jor bleeding, uncontrolled hypertension, haemoglobin <10.0 g/dl, platelet 
count <100,000/μl or a white blood cell count <3,000/μl; a requirement 
for ongoing treatment with a thienopyridine; AF secondary to reversible 
disorders (e.g., thyrotoxicosis); left ventricular aneurysm or atrial myxoma; 
an estimated life expectancy <12 months; planned surgery or intervention 
within the study period; a history of hepatitis B or C or HIV infection; creati-
nine clearance < 30 ml/minute (min); a cardiac pacemaker or implantable 
cardioverter-defibrillator; investigational drug treatment (including edoxa-
ban) or device implantation in the last three months, or plan to receive such 
therapy during the study period. impaired hepatic function.
AF = atrial fibrillation; TIA = transient ischemic attack; CHADS2 = Congestive heart failure, hypertension, age, diabetes, stroke score.
table 4 - Key patient characteristics of included studies.
Study age
(years)
Female 
gender
Htn diabetes Heart 
failure
Prior-
myocardial 
infarction
Parox-
smal 
aF
Prior 
stroke 
or tia
Warfarin 
naïve 
patients
cHadS2 
score
>2
ARISTOTLE 70 36% 87% 25% 36% 15% 16% 20% 57% 30%
ARISTOTLE-J 70 20% 83% 23% 1% NA 0 28% 16% 57%
Chung 2011 65 36% 71% 30% 28% NA NA 19% NA 49%
PETRO 70 18% 71% 25% 29% NA 23% 17% NA NA
RE-LY 72 37% 79% 23% 79% 17% 33% 20% 50% 33%
ROCKET-AF 73 40% 90% 40% 63% 17% 18% 55% 62% 100%
Weitz 2010 65 41% NA NA NA NA NA NA 66% 100%
AF=atrial fibrillation; CHADS2=Congestive heart failure, hypertension, age, diabetes, stroke score; HTN=hypertension; 
NA=not available or applicable; TIA=transient ischemic attack.
(namely the focus on a common patient 
subset treated with the same comparator) 
hold true. The internal validity of included 
studies was high, especially given the logis-
tical challenges involved in the conduct of 
a double-blind trial when warfarin is the 
control treatment (Table 5). 
Pair-wise meta-analysis. First, we conducted 
a standard pair-wise meta-analysis pooling 
all novel oral anticoagulants together and 
comparing them against warfarin perform-
ing a random-effect model. After a weighted 
average follow-up of 23 months, novel oral 
anticoagulants were associated with sig-
nificant reductions in the risk of stroke or 
systemic embolism (OR=0.81 [0.71-0.92], 
I2=23%) all cause death (OR=0.88 [0.82-
0.95], I2=0%), in comparison to warfarin, 
with a favorable trend for major bleeding 
(OR=0.83 [0.68-1.02], I2=73%). Con-
versely, aggregate analysis showed a simi-
lar or slightly increased risk of study drug 
discontinuation with novel oral antico-
agulants (OR=1.18 [0.96-1.46], I2=92%) 
versus warfarin. However, both estimates 
regarding major bleeding and drug discon-
tinuation were statistically inconsistent, 
suggesting different effects of the different 
anticoagulants. Funnel plot inspection sug-
gested the presence of small study effects 
due to the inclusion of phase II trials with 
a small sample size. However, sensitivity 
novel anticoagulants for aF
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table 5 - Risk of bias assessment of included studies.
adequate
sequence 
generation?
allocation 
concealment 
used?
Blinding? concurrent 
therapies 
similar?
incomplete 
outcome 
data ad
dressed?
uniform
and explicit 
out come 
definitions?
Free of 
selective 
outcome 
reporting?
Free 
of 
other 
bias?
Over
all 
risk of 
bias?
ARISTOTLE Yes (computed 
generated 
sequence)
Yes (interactive
voice response
system)
Double blind, 
bouble 
dummy
Yes 
(differences 
<1%)
Yes Yes Yes Yes Low
ARISTOTLE-J Unclear Yes (interactive 
voice response 
system)
Double 
blind
Yes
(differences
<3%)
Not 
addressed
Yes Unclear Yes Moderate
Chung 2011 Yes (computed 
generated 
sequence)
Yes (interactive 
voice response 
system)
Blind to dose 
of edoxaban,
but open
to identity
of edoxaban 
warfarin
Yes 
(differences 
<1%)
Not 
addressed
Yes Unclear Yes Moderate
PETRO Unclear Yes (interactive 
voice response 
system)
Double 
blind to dose 
of dabigatran 
but open 
to identity 
of dabigatran 
and warfarin
Yes
(differences 
<5%)
Not 
addressed
Yes Unclear Yes Moderate
RE-LY Yes (computed 
generated 
sequence)
Yes (interactive 
voice response 
system)
Double 
blind
Yes
(differences 
<1%)
Yes Yes Yes Yes Low
ROCKET-AF Yes (computed 
generated 
sequence)
Yes (interactive 
voice response 
system)
Double blind, 
double 
dummy
Yes
(differences 
<1%)
Yes Yes Yes Yes Low
Weitz 2010 Yes (computed 
generated 
sequence)
Yes (interactive 
voice response 
system)
Blind to dose 
of edoxaban, 
but open
to identity 
of edoxaban 
and warfarin
Yes
(differences 
<5%)
Not 
addressed
Yes Yes Yes Low
table 6 - Key excluded studies.
Study Study drug reason for exclusion
AVERROES Apixaban Selective inclusion of warfarin ineligible patients
Ellis 2009 Tecarfarin Non-randomized design
ENGAGE AF-TIMI 48 Edoxaban Ongoing
RE-LY – CHADS2 substudy Dabigatran Duplicate publication
RE-LY – CHA2DS2-VASc substudy Dabigatran Duplicate publication
RE-LY – Prior stroke/TIA substudy Dabigatran Duplicate publication
ROCKET-AF – Renal failure substudy Rivaroxaban Duplicate publication
CHADS2=Congestive heart failure, hypertension, age, diabetes, stroke score; CHA2DS2-VASc=Congestive heart failure, hyper-
tension, age, diabetes, stroke-vascular disease, age, sex category score; TIA=transient ischemic attack.
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table 7 - Clinical outcomes in included studies*.
Stroke or systemic 
embolism death Major bleeding drug discontinuation
Apixaban Or=0.78 (0.62-0.96) 
vs warfarin;
OR=1.17 (0.85-1.63) 
vs HD dabigatran;
OR=0.85 (0.62-1.17) 
vs LD dabigatran;
OR=3.70 (0.43-50.1) 
vs HD edoxaban;
OR=1.43 (0.25-12.5) 
vs LD edoxaban;
OR=0.89 (0.65-1.20) 
vs rivaroxaban
OR=0.89 (0.75-1.05) 
vs warfarin;
OR=1.01 (0.79-1.29) 
vs HD dabigatran;
OR=0.98 (0.77-1.25) 
vs LD dabigatran;
OR=2.78 (0.46-16.7) 
vs HD edoxaban;
OR=1.16 (0.20-5.26) 
vs LD edoxaban;
OR=1.07 (0.82-1.41) 
vs rivaroxaban
Or=0.68 (0.58-0.80) 
vs warfarin;
Or=0.73 (0.57-0.93) 
vs Hd dabigatran;
OR=0.85 (0.66-1.08) 
vs LD dabigatran;
OR=0.57 (0.26-1.30) 
vs HD edoxaban;
OR=1.19 (0.49-2.86) 
vs LD edoxaban;
Or=0.66 (0.52-0.84) 
vs rivaroxaban
OR=0.90 (0.78-1.03) 
vs warfarin;
Or=0.64 (0.52-0.78) 
vs Hd dabigatran;
Or=0.66 (0.54-0.81) 
vs ld dabigatran;
Or=0.17 (0.02-0.78) 
vs Hd edoxaban;
OR=0.58 (0.05-4.17) 
vs LD edoxaban;
OR=0.82 (0.67-1.01) 
vs rivaroxaban
High-dose 
dabigatran 
Or=0.66 (0.52-0.84) 
vs warfarin;
Or=0.72 (0.56-0.93) 
vs ld dabigatran;
OR=3.13 (0.37-50.0) 
vs HD edoxaban;
OR=1.20 (0.21-10.3)
vs LD edoxaban;
OR=0.76 (0.55-1.03) 
vs rivaroxaban
OR=0.88 (0.74-1.05) 
vs warfarin;
OR=0.97 (0.81-1.16) 
vs LD dabigatran;
OR=2.86 (0.46-20.2) 
vs HD edoxaban;
OR=1.16 (0.21-5.56) 
vs LD edoxaban;
OR=1.06 (0.80-1.41) 
vs rivaroxaban
OR=0.93 (0.77-1.12) 
vs warfarin; 
OR=1.16 (0.96-1.41) 
vs LD dabigatran;
OR=0.78 (0.35-1.82) 
vs HD edoxaban;
OR=1.64 (0.66-4.07) 
vs LD edoxaban;
OR=0.91 (0.70-1.19) 
vs rivaroxaban
Or=1.41 (1.21-1.65) 
vs warfarin;
OR=1.04 (0.89-1.20) 
vs LD dabigatran;
OR=0.27 (0.03-1.23) 
vs HD edoxaban;
OR=0.93 (0.08-6.67) 
vs LD edoxaban;
Or=1.29 (1.05-1.60) 
vs rivaroxaban
Low-dose 
dabigatran 
OR=0.91 (0.72-1.15) 
vs warfarin; 
OR=4.39 (0.50-50.0) 
vs HD edoxaban;
OR=1.69 (0.29-14.3) 
vs LD edoxaban;
OR=1.04 (0.77-1.42) 
vs rivaroxaban
OR=0.91 (0.76-1.09) 
vs warfarin;
OR=2.78 (0.44-1.67) 
vs HD edoxaban;
OR=1.13 (0.21-5.26) 
vs LD edoxaban;
OR=1.10 (0.83-1.45) 
vs rivaroxaban
Or=0.80 (0.66-0.97) 
vs warfarin;
OR=0.67 (0.30-1.56) 
vs HD edoxaban;
OR=1.41 (0.57-3.45) 
vs LD edoxaban;
OR=0.78 (0.60-1.02) 
vs rivaroxaban
Or=1.36 (1.16-1.58) 
vs warfarin;
OR=0.26 (0.03-1.19) 
vs HD edoxaban;
OR=0.88 (0.08-6.30) 
vs LD edoxaban;
Or=1.24 (1.01-1.54) 
vs rivaroxaban
High-dose 
edoxaban
OR=0.21 (0.02-1.78) 
vs warfarin;
OR=0.40 (0.02-5.26) 
vs LD edoxaban; 
OR=0.24 (0.02-2.04) 
vs rivaroxaban
OR=0.32 (0.05-1.94) 
vs warfarin;
OR=0.44 (0.06-2.43) 
vs LD edoxaban;
OR=0.38 (0.06-2.44) 
vs rivaroxaban
OR=1.19 (0.53-2.60) 
vs warfarin;
OR=2.04 (0.84-5.55)
vs LD edoxaban;
OR=0.85 (0.39-1.99) 
vs rivaroxaban
Or=5.29 (1.15-49.7)
vs warfarin;
OR=3.33 (0.94-16.7) 
vs LD edoxaban;
Or=4.76 (1.05-4.76) 
vs rivaroxaban
Low-dose 
edoxaban
OR=0.55 (0.07-3.10) 
vs warfarin; 
OR=0.62 (0.07-3.70) 
vs rivaroxaban
OR=0.78 (0.17-4.28) 
vs warfarin;
OR=0.93 (0.20-5.26) 
vs rivaroxaban
OR=0.57 (0.24-1.37) 
vs warfarin;
OR=0.56 (0.22-1.37) 
vs rivaroxaban
OR=1.53 (0.21-16.8) 
vs warfarin;
OR=1.41 (0.20-16.6) 
vs rivaroxaban
Rivaroxaban OR=0.87 (0.71-1.07) 
vs warfarin
OR=0.83 (0.66-1.03) 
vs warfarin
OR=1.02 (0.85-1.23) 
vs warfarin 
OR=1.09 (0.94-1.26) 
vs warfarin
*reported as odds ratio (OR) with 95% credible intervals. Bold face highlights credibly different OR. HD=High-dose; LD= Low-dose.
analysis excluding all studies with sample 
size ≤5,000 patients confirmed in magni-
tude and direction our overall findings. 
Network meta-analysis. Warfarin-controlled 
network meta-analysis enabled the head-to-
head comparison of each novel oral antico-
agulant against warfarin as well as against 
each other individual drug (Table 7). 
After a weighted average follow-up of 23 
months, apixaban and high-dose dabiga-
novel anticoagulants for aF
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tran proved similarly effective in prevent-
ing stroke or systemic embolism in com-
parison to warfarin (OR=0.78 [0.62-0.96] 
for apixaban and OR=0.66 [0.52-0.84] for 
high-dose dabigatran vs warfarin; indirect 
OR of apixaban versus high-dose dabiga-
tran=1.17 [0.85-1.63]). However, apixa-
ban was associated with fewer major bleed-
ings than high-dose dabigatran (OR=0.73 
[0.57-0.93]) and fewer drug discontinu-
ations than either high-dose dabigatran 
(OR=0.64 [0.52-0.78]) or low-dose dabiga-
tran (OR=0.66 [0.54-0.81]).
Low-dose dabigatran was associated with 
fewer major bleedings than warfarin 
(OR=0.80 [0.66-0.97]), but was discon-
tinued more frequently (OR=1.36 [1.16-
1.58]) than the older agent. Conversely, ri-
varoxaban did not appear to reduce the risk 
of stroke or systemic embolism (OR=0.87 
[0.71-1.07]) or major bleeding incompari-
son to warfarin (OR=0.87 [0.71-1.07]) 
and was associated with credibly more ma-
jor bleedings in comparison to apixaban 
(OR=1.52 [1.19-1.92]). 
Data for edoxaban were largely inconclu-
sive, as the pertinent phase III pivotal trial 
is still ongoing (i.e. ENGAGE AF-TIMI 
48). Nonetheless, high-dose edoxaban was 
discontinued more frequently than war-
farin (OR=5.29 [1.15-49.7]), apixaban 
(OR=5.89 [1.28-50.1]) and rivaroxaban 
(OR=4.76 [1.05-4.76]).
diScuSSiOn
This systematic review provides direct 
evidence that novel oral anticoagulants 
represent a paradigm shift in the manage-
ment of atrial fibrillation, as they are asso-
ciated with significant benefits on the risk 
of stroke or systemic embolism and death. 
In addition, by exploiting the use of war-
farin as a common comparator within the 
framework of a network meta-analysis, this 
study shows that both apixaban and high-
dose dabigatran are superior to warfarin 
for the prevention of thromboembolism 
with a similar efficacy, and that apixaban 
appears to be better tolerated and associat-
ed with reduced bleeding when compared 
with dabigatran.
Apixaban is an inhibitor of coagulation 
factor Xa, orally bioavailable and mostly 
metabolized by the hepatic CYP3A4 sys-
tem (15, 27). The recommended dose is 5 
mg twice daily but the dose is to be reduced 
with renal impairment. The use of apixa-
ban is discouraged in patients with severe 
liver disease, and caution should be used 
when CYP3A4 or P-glycoprotein inhibi-
tors or inducers are used concomitantly. 
As for all factor Xa inhibitors routine mon-
itoring of efficacy is not available, as anti-
Xa activity may determined but it is often 
not available. To date, no specific antidote 
to reverse the effects of apixaban is known. 
The superior efficacy in preventing throm-
boembolism associated with a reduction 
in major bleeding when compared with 
warfarin suggest that in patients without 
contraindications, apixaban is preferable 
to warfarin. The indirect comparisons 
of apixaban with the other oral antico-
agulants dabigatran, edoxaban, and rivar-
oxaban, show that efficacy of apixaban in 
preventing thromboembolism is not sta-
tistically different from the others. A nu-
merically higher risk of thromboembolism 
was seen for apixaban in comparison with 
high-dose dabigatran (OR=1.17), high-
dose edoxaban (OR=3.70) and low-dose 
edoxaban (OR=1.43), but for all these cas-
es the confidence interval largely crossed 
the unity meaning that the difference was 
not statistically credible, for which the su-
periority of these agents in comparison 
with apixaban could not be proven (nor 
negated). In terms of safety, apixaban was 
associated with significantly fewer major 
bleeding episodes when compared with 
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warfarin, high-dose dabigatran and rivar-
oxaban (ORs between 0.66 and 0.73) and 
no significant differences compared with 
low-dose dabigatran or edoxaban with all 
ORs crossing the unity.
Dabigatran, on the other hand, is a coagu-
lation factor IIa (thrombin) inhibitor (15, 
28). Dabigatran etexilate is orally bioavail-
able and rapidly converted in dabigatran 
under the effects of plasma and hepatic 
esterases. Dabigatran is cleared by the kid-
ney, and the dose recommended by the 
Food and Drug Administration is 150 mg 
twice daily for creatinine clearance >30 
ml/min*m2, with the dose reduced to 75 
mg twice daily for creatinine clearance ≤30 
ml/min*m2, whereas its use it not recom-
mended for lower creatinine clearance (i.e. 
≤15 ml/min*m2). At odds with apixaban, 
dabigatran is not metabolized by the liver 
and it has no drug-to-drug interaction with 
CYP3A4 inhibitors or inducers, whereas it 
still interacts with P-glycoprotein inhibi-
tors or inducers. Dabigatran affects both 
activated partial thromboblastin and eca-
rin clotting times, but routine monitoring 
of efficacy is not indicated. Like apixaban, 
no specific antidote to reverse the effects of 
dabigatran is known. 
The RELY trial appraised also the 110 mg 
twice daily dose (low-dose) of dabigatran 
which is not approved for clinical use in 
the US but only in Europe (9). In this 
study, in which randomization to dabi-
gatran (one of two doses) or warfarin was 
open label, high-dose dabigatran showed 
greater efficacy in prevention of throm-
boembolism and a similar effect on major 
bleeding. These effects were associated 
with an important reduction by dabigatran 
in intracranial bleeding and a significant 
increase in gastrointestinal bleeding with 
dabigatran when compared with warfarin. 
Moreover, dabigatran was associated with 
a higher discontinuation rate than warfa-
rin. In the indirect analyses, when com-
pared with apixaban, dabigatran showed 
a similar efficacy in the prevention of 
thromboembolism (OR 1.17 [0.85-1.63] 
favoring dabigatran) but a credibly higher 
rate of major bleeding or discontinuation. 
Considering these factors, in the absence 
of contraindications, apixaban may appear 
superior to dabigatran. Special conditions 
such as the presence of liver impairment or 
concomitant use of CYP34A inhibitors or 
inducers may however prevent the use of 
apixaban and not of dabigatran. Additional 
head-to-head studies sufficiently powered 
to directly compare efficacy of the 2 drugs 
are needed, but unlikely to be available in 
the next 4-6 years. Notably, apixaban and 
dabigatran are both approved for the use 
in patients with non-valvular atrial fibril-
lation in the USA, whereas edoxaban and 
rivaroxaban are not. The European Medi-
cines Agency has already approved both 
110 mg and 150 mg twice daily regimens of 
dabigatran, but has not yet approved other 
novel oral anticoagulants for the treatment 
of atrial fibrillation.
Edoxaban is an additional factor Xa inhibi-
tor that has been studied in a smaller num-
ber of patients (14, 15). It is also orally bio-
available, it has renal clearance and minor 
hepatic metabolism. Data on efficacy and 
safety are however limited, awaiting the 
pertinent phase III pivotal trial (ENGAGE-
TIMI 48) (14).
Rivaroxaban is another factor Xa inhibi-
tor which is orally bioavailable, metabo-
lized by liver and kidney (15, 29).The 
dose used in the large ROCKET-AF study 
was 20 mg daily (to be reduced to 15 mg 
if creatinine clearance between 30-49 ml/
min*m2). Like apixaban, it interacts with 
CYP3A4 or P-glycoprotein inhibitors and 
inducers, and should not be used in pa-
tients with advanced liver disease. As for 
all factor Xa inhibitors routine monitoring 
of efficacy is not available, as anti-Xa ac-
tivity may be determined but it is uncom-
novel anticoagulants for aF
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monly used. In the ROCKET-AF trial, ri-
varoxaban was shown to be non-inferior to 
warfarin in terms of thromboembolism or 
stroke. In this indirect comparison, rivar-
oxaban appeared to have similar efficacy in 
preventing thromboembolism when com-
pared with the apixaban and dabigatran 
but was associated with significantly great-
er bleeding compared with apixaban. The 
once daily administration schedule may 
appear favorable to patient compliance as 
compared with apixaban and dabigatran, 
but the superior efficacy of apixaban and 
dabigatran, and greater safety of apixaban 
make rivaroxaban a less favorable choice. 
There is no specific antidote for rivaroxa-
ban, however, a recent report described 
full reversibility of rivaroxaban effects (but 
not of dabigatran effects) with protrombin 
complex concentrate (30). 
If confirmed in additional studies which 
would need to include also a determina-
tion of the effects of prothrombin complex 
concentrate on apixaban, this may support 
the use of rivaroxaban in settings in which 
need for rapid reversal may be anticipated. 
The lack of requirement for monitoring 
with these agents has been viewed mostly 
as an advantage, but it can clearly repre-
sent a disadvantage when non-compliance 
with therapy or overdose is suspected. The 
wide-spread availability of INR monitoring 
for warfarin use has been advocated as a 
reason to prefer warfarin to these new an-
ticoagulants, however, the lack of reduced 
bleeding with warfarin and INR monitor-
ing in comparison with the use of these 
agents without monitoring argues that the 
availability of INR monitoring is not a suf-
ficient reason to advocate for warfarin. 
The lack of an antidote for the new agents 
has also been viewed as a limitation, and it 
certainly is. However the same holds true 
for warfarin considering that vitamin K is 
a slow acting antidote and is likely to re-
verse the effects of warfarin in the same 
time needed for any of these new agents to 
revert their effects without antidote.
In addition, direct costs will be much higher 
with these new agents than with warfarin. 
Whereas a cost-benefit or cost-utility analy-
sis was of course beyond our scope, we can 
provide some informed speculations. First, 
warfarin costs are very low if we focus only 
on the cost of the pill itself, but if we add 
the indirect yet remarkable costs of dedicat-
ed INR monitoring centers, days off work 
to get blood draws, and, most importantly, 
the cost of recurrent thromboses and bleed-
ing complications, then a warfarin regimen 
does not appear as economically appealing 
as it initially seemed. Moreover, taking for 
granted the reduction in the risk of death 
with novel oral anticoagulants, which is a 
rather uncommon finding in the realm of 
thromboembolism management, we should 
ask ourselves whether it is ethically sound 
to deny this drugs to any patient suitable 
for such life-saving therapy. More practical-
ly, we may anticipate that uptake of these 
new drugs will be slow, yet progressively 
increase. It can also be conceived that these 
drugs might be cost-saving (thus proving 
cheaper than warfarin) in those intolerant 
to warfarin or failing warfarin (i.e. experi-
encing a thromboembolic events despite ad-
equate INR). Conversely, we might expect 
novel oral anticoagulants to be reasonable 
cost-effective (thus associated with a social-
ly acceptable premium price), in patients at 
moderate to high thromboembolic risk and 
concomitantly at moderate to high bleeding 
risk with warfarin. It is unclear what cost 
analyses will show in other patient subsets. 
Thus, further detailed analyses, including 
also real-world patients (typically excluded 
from pivotal randomized trials) are war-
ranted.
Finally, the unprecedented reduction in 
mortality with novel oral anticoagulants 
might appear surprising. Awaiting for fur-
ther sub-analyses of the included trials, we 
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may suggest a number of explanations for 
this finding. First, novel oral anticoagulant 
might prove life-saving because they main-
tain more often the patient in the correct 
therapeutic window. This means fewer 
thromboembolic episodes as well as fewer 
bleedings, both of which might be fatal if 
very severe or occurring in very sensible 
organs or systems. In addition, novel oral 
anticoagulants might be suitable for more 
patients than warfarin alone, and thus treat 
adequately a subset of patient who other-
wise discontinue or are never treated with 
warfarin. Finally, we cannot exclude pleio-
tropic effects, such as those provided, in a 
very different context, by statins. However, 
much more clinical and pathophysiologic 
studies are required before considering the 
life-saving properties of novel oral antico-
agulants as a given fact.
Limitations
Drawbacks of meta-analyses in general are 
well known, and additional limitations of 
network meta-analyses can be envisioned 
(31-33). Nonetheless, we emphasize that 
clinical decision making is often based on 
incomplete evidence, and large head-to-
head randomized trials of novel oral anti-
coagulants for atrial fibrillation do not ex-
ist and are not foreseeable for the next 4-6 
years, at least. Indeed, we remain positive 
that network meta-analyses based on indi-
rect comparisons are exquisitely scientific, 
as they inform on what will be the out-
comes of future randomized clinical trials, 
and thus are uniquely falsifiable, in keeping 
with Popper’s theories (34). In addition, we 
decided a priori to exclude studies, remote 
or recent, enrolling patients unsuitable for 
warfarin therapy such as those candidates 
to low-dose aspirin (35), clopidogrel (36), 
or left atrial appendage closure (37), under 
the assumption that these subjectes were 
unlikely to have a risk-benefit profile simi-
lar to those suitable for long-term warfarin 
therapy. Yet, this focus on warfarin-eligibile 
patients limited the scope of the present 
network meta-analysis. In addition, data 
on edoxaban were limited, and thus results 
on this specific agent should be mainly con-
sidered hypothesis-generating. Other draw-
backs of our work include the focus on 4 
end-points only. Specifically, we did not 
explore in detail reasons for drug discon-
tinuation (e.g. dyspepsia for dabigatran) 
nor causes for death (e.g. myocardial infarc-
tion) or type of bleeding (e.g. intracranial 
versus gastrointestinal). Further confirma-
tory analyses, beyond indirect comparisons 
(38-43), are warranted for these important 
details, but are beyond the scope of the this 
review.
cOncluSiOn
Novel oral anticoagulants represent a para-
digm shift in the management of non-val-
vular atrial fibrillation. This study shows 
that both apixaban and dabigatran (150 
mg) are superior to warfarin for the pre-
vention of thromboembolism with a simi-
lar efficacy, and that apixaban appears to 
be better tolerated and associated with re-
duced bleeding when compared with dabi-
gatran. Considering that ‘one size’ may not 
fit all patients, apixaban may represent the 
preferred agent for the majority of patients 
with non-valvular atrial fibrillation. Dabi-
gatran may be considered for patients who 
are not candidates for apixaban. Rivaroxa-
ban may be a less favorable choice in com-
parison to apixaban or dabigatran whereas 
it remains a valid alternative to warfarin. 
The data on edoxaban is to date inconclu-
sive. Given the superiority in one or more 
aspects (efficacy, safety, ease-of-use), war-
farin should not remain first choice of an-
ticoagulation in patients with non-valvular 
atrial fibrillation and at least moderate 
thromboembolic risk.
novel anticoagulants for aF
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